The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,586.00
Bid: 12,584.00
Ask: 12,588.00
Change: -4.00 (-0.03%)
Spread: 4.00 (0.032%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: European stocks edge higher in cautious trade

Thu, 06th Apr 2023 08:37

(Alliance News) - Stock prices in London opened higher on Thursday, but sentiment was fragile amid fears of an economic slowdown in the US, and heightened geopolitical tensions.

The FTSE 100 index opened up 28.70 points, 0.4%, at 7,691.64. The FTSE 250 was up 38.53 points, 0.2%, at 18,639.95, and the AIM All-Share was up 1.81 points, 0.2%, at 805.50.

The Cboe UK 100 was up 0.5% at 769.72, the Cboe UK 250 was up 0.6% at 16,231.96, and the Cboe Small Companies was down 0.3% at 13,157.49.

In European equities, the CAC 40 in Paris and the DAX 40 in Frankfurt were each up 0.1%.

Financial markets in the London, Paris, Frankfurt and New York will be closed on Friday to mark Good Friday. However, the US jobs report will still be reported at 1330 BST on Friday.

UK and European markets will remain closed on Easter Monday, while New York re-opens.

Annual growth in UK house prices weakened to levels not seen since October 2019, according to data from Halifax. According to the mortgage lender, average house prices edged up 0.8% in March on a monthly basis. Growth slowed from a 1.2% climb in February. Annually, growth in house prices slowed to 1.6% in March, from the 2.1% climb seen in each of the previous three months.

In London, residential property market slowdown fears hit shares in housebuilder Barratt, down 1.8%, and estate agent Savills, shedding 3.6%.

The dollar was slightly stronger in early exchanges.

Sterling was quoted at USD1.2461 early Thursday, lower than USD1.2471 at the London equities close on Wednesday. The euro traded at USD1.0903, down from USD1.0919. Against the yen, the dollar was quoted at JPY131.36, up versus JPY130.94.

In the US on Wednesday, Wall Street ended mixed, with the Dow Jones Industrial Average ending up 0.2%, the S&P 500 down 0.3% and the Nasdaq Composite down 0.3%.

"A number of US releases suggested that the economy is beginning to wilt under the pressure of the Federal Reserve's aggressive hiking policy, with attention now turning to the scale of a recession, rather than whether one will happen," said interactive investor analyst Richard Hunter.

On Wednesday, survey data from the Institute for Supply Management indicated that the slowdown in the US services sector was faster than expected. The ISM services PMI registered 51.2 in March, its third consecutive month of growth, but down from 55.1 points in February. Markets had expected the reading to dip to 54.5 points, according to FXStreet.

Meanwhile, in Asia on Thursday, the Nikkei 225 index in Tokyo closed down 1.1%. The S&P/ASX 200 in Sydney closed down 0.3%. In China, the Shanghai Composite was marginally lower, while the Hang Seng index in Hong Kong was marginally higher.

Sentiment was unsteady as geopolitical tensions between the world's two largest economies escalated. China sent warships through waters around Taiwan on Thursday as it vowed a "resolute response" to the island's president meeting US House Speaker Kevin McCarthy.

"The fractious relationship between the world's two largest economies is never far from investors' minds, and the latest development was enough to unsettle sentiment, despite some stronger economic readings, most notably a further accelerating services sector in China," ii's Hunter commented.

China's services sector continued to rebound in March, according to the latest survey data on Thursday.

The Caixin services purchasing managers' index rose to 57.8 points in March from 55.0 in February, rising further above the 50-point mark that separates expansion from contraction. It shows a sharp acceleration in the pace of growth.

It was the strongest expansion seen since November 2020, and the third consecutive month of growth.

Meanwhile, developments in Middle Eastern relations may also unnerve the US.

Top diplomats from Middle East rivals Iran and Saudi Arabia met in Beijing on Thursday, pledging to work together to bring "security and stability" to their turbulent region following a surprise China-brokered deal.

In a joint statement released after talks between Iranian Foreign Minister Hossein Amir-Abdollahian and Saudi counterpart Prince Faisal bin Farhan, the two sides vowed to continue to work together to improve ties.

"The oil-rich kingdom has restricted oil output twice against the wishes of the United States, and it has forged goodwill with its neighbouring country, Iran—a country with whom the Saudis have long been at odds," said Zaye Capital Markets' Naem Aslam.

"This predicament has led traders to believe that they need to use extreme caution when deciding which asset class to support," he added.

Brent oil was trading at USD84.56 a barrel early Thursday, up from USD84.48 late Wednesday. It was up sharply from USD79.14 at the market close on Friday, before the surprise production cut announcement from Opec+ last weekend.

In the FTSE 100, Shell rose 2.0% in early trading.

The oil major said it expects a rise in Integrated Gas production in the first quarter of 2023, though it predicted an adjusted corporate loss on a tax hit.

Shell predicted an adjusted loss in its corporate segment between USD900 million and USD1.2 billion, widening from USD600 million in the fourth quarter of 2022. The outcome "includes one-off tax charges", the company said.

It expects Integrated Gas adjusted earnings pre-tax depreciation between USD1.2 and USD1.6 billion, compared to USD1.4 billion in the fourth quarter.

Upstream adjusted earnings are expected between USD2.8 billion to US3.1 billion, compared to USD2.9 billion. For Integrated Gas, it forecast production between 930,000-970,000 barrels of oil equivalent, up from 917,000 boe in the fourth quarter. Upstream production volumes are expected to be within a similar range to the previous quarter, between 1.8 million and 1.9 million boe per day, compared to 1.85 million in the fourth quarter.

Astrazeneca rose 0.9%, on news UK's NHS has approved the use of one of its drugs, which could benefit hundreds of patients with breast cancer and prostate cancer.

Men with advanced prostate cancer and women with HER2-negative early breast cancer who are at high risk of the disease returning will be able to access olaparib through the NHS in England. The decision has been overwhelmingly welcomed, with praise from cancer charities and scientists.

Reckitt Benckinser, ConvaTec and Rentokil fell by 1.9%, 1.2% and 1.3% respectively, as the stocks went ex-dividend.

Gold was quoted at USD2,013.40 an ounce, lower than USD2,021.30, but also up sharply from USD1,979.05 last Friday.

In the FTSE 250, Ferrexpo rose 3.5%.

The iron ore pellet maker updated on its production in the first quarter. Total iron ore pellet production doubled to 901,000 tonnes from the 420,000 tonnes in the fourth quarter. The rise was mostly down to the improvement in electricity supply to its operations in Ukraine, the firm said. This enabled Ferrexpo to restart a second pelletiser line in late February.

Among London's small-caps, Robert Walters fell 3.5%.

The recruitment firm reported a "slower start" to 2023. Net fee income in the first quarter rose 4% year-on-year to GBP102.4 million. It grew 16% in Europe and 18% in Other Internation, helping to offset a 9% decline in the UK and a 1% fall in Asia Pacific. However, on a constant currency basis, net fee income was flat.

"Uncertain global macroeconomic conditions continued to impact recruitment activity levels across a number of the group's markets and disciplines," the firm said.

Robert Walters pointed to the "relatively robust" market fundamentals such as vacancy levels and salary inflation, as well as a global shortage of qualified professionals. It expects the rebound in the Chinese economy, easing inflation and the stabilisation of the technology sector to boost the global outlook.

Still to come on Thursday's economic calendar, there's a UK construction PMI print at 0930 BST. The US weekly unemployment insurance claims will be released at 1330 BST

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.